HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NJ Senators Tell Congress 'Complicated Legal Framework' Hurts CBD Firms

Executive Summary

NJ senators say although FDA deems dietary ingredients and food additives with CBD as unlawful, in the past three years more than 1,500 CBD products have come to market “without a clear approach for regulation or any plan from the FDA to balance consumer access and protect consumer health.”

You may also be interested in...



Without US CBD Guidance, Low-Quality Supplements, State Rules Hurt Industry

Responsible CBD supplement marketers are disadvantaged against bad actors with products taking up shelf space in “disloyal” retailers as federal regulatory limbo drags on, says nutritional science expert Duffy McKay. Patchwork of state regulations on CBD also create challenges.

FDA Unfairly ‘Maligning’ Responsible CBD Product Marketers – Council For Responsible Nutrition

Dietary supplement trade groups reacted on 26 November – in CRN’s case with umbrage – to the US Food and Drug Administration’s latest barrage of cannabidiol (CBD)-themed warning letters and accompanying update to consumers regarding CBD safety.

FDA Suggests Legislation To Streamline Enforcement In Supplement Market

Congress should consider legislation authorizing agency to conduct enforcement more directly, says Associate Commissioner Schiller. In FDLI conference keynote, he discussed compliance with FDA regulations across markets it regulates, but made specific example of saying FDA is comparatively hamstrung in regulating businesses marketing products labeled as supplements.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS149407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel